

Xenogeneic CAR-T Therapy for Canine B-Cell Lymphoma

The purpose of this study is to determine the safety of combining a novel chemotherapy treatment with genetically modified human white blood cells (xenogeneic CAR-T cells) in dogs diagnosed with CD20-positive B-cell lymphoma. A secondary objective is to determine the antitumor effectiveness of this treatment protocol.

What qualifies my pet?

All breeds except Boxers
Body weight 10-50 kg
Treatment naïve or relapsed
peripheral multicentric lymphoma,
substage A, non-GI lymphoma
Minimum 3 enlarged peripheral
lymph nodes
No evidence of kidney, liver, or heart
disease
Normal calcium, adequate
electrolytes, adequate bilirubin
Platelet count > 100,000/ μ L, HCT
>25%, ANC >2000/ μ L
Not otherwise immunocompromised
No gastrointestinal involvement
No lung involvement
Final enrollment confirmation of
CD20-positive immunophenotype

Client compensation

\$2000 will be credited to your Veterinary Medical Center account for future care of your pet upon completion of the Day 21 visit (prorated for early non-animal welfare withdrawal)

**Learn more
and pre-screen here:**

